Artificial Intelligence Paper Outlines FDA’s Approach to Protect Public Health and Promote Ethical Innovation
- The FDA released a document on how its medical product centers are collaborating to ensure public health and promote responsible innovation in AI used in medical products.
- The document highlights the potential of AI, including machine learning, to transform healthcare and emphasizes promoting health equity through secure, safe, ethical, and effective AI development.
- It stresses the importance of careful management of AI technologies throughout the medical product life cycle for successful development, deployment, use, and maintenance.
- The FDA outlines four priorities for cross-center collaboration to ensure consistency across the organization.
- Published by CBER, CDER, CDRH, and OCP, the document reflects the FDA’s commitment to protecting public health and driving innovation.
– The document complements the “Artificial Intelligence and Machine Learning Software as Medical Device Action Plan” published in January 2021.
